Dae-Won Lee1, Sae-Won Han1,2, Yongjun Cha1, Jeong Mo Bae3, Hwang-Phill Kim2,4, Jaemyun Lyu5, Hyojun Han5, Hyoki Kim5, Hoon Jang6, Duhee Bang6, Iksoo Huh7, Taesung Park7, Jae-Kyung Won3, Seung-Yong Jeong8, Kyu Joo Park8, Gyeong Hoon Kang3, Tae-You Kim1,2,4. 1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. 2. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea. 3. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. 4. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea. 5. Celemics, Inc, Seoul, Korea. 6. Department of Chemistry, College of Science, Yonsei University, Seoul, Korea. 7. Department of Statistics, Seoul National University, Seoul, Korea. 8. Department of Surgery, Seoul National University Hospital, Seoul, Korea.
Abstract
BACKGROUND: Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor β [TGF-β]) was performed for 516 patients with stage III or high-risk stage II CRC treated with surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy. The associations between critical pathway mutations and relapse-free survival (RFS) and overall survival were analyzed. The associations were further analyzed according to the tumor location. RESULTS: The mutation rates for the WNT, P53, RTK-RAS, PI3K, and TGF-β pathways were 84.5%, 69.0%, 60.7%, 30.0%, and 28.9%, respectively. A mutation in the PI3K pathway was associated with longer RFS (adjusted hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.36-0.99), whereas a mutation in the RTK-RAS pathway was associated with shorter RFS (adjusted HR, 1.60; 95% CI, 1.01-2.52). Proximal tumors showed a higher mutation rate than distal tumors, and the mutation profile was different according to the tumor location. The mutation rates of Kirsten rat sarcoma viral oncogene homolog (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA), and B-Raf proto-oncogene serine/threonine kinase (BRAF) were higher in proximal tumors, and the mutation rates of adenomatous polyposis coli (APC), tumor protein 53 (TP53), and neuroblastoma RAS viral oncogene homolog (NRAS) were higher in distal tumors. The better RFS with the PI3K pathway mutation was significant only for proximal tumors, and the worse RFS with the RTK-RAS pathway mutation was significant only for distal tumors. CONCLUSIONS: A PI3K pathway mutation was associated with better RFS for CRC patients treated with adjuvant chemotherapy, and an RTK-RAS pathway mutation was associated with worse RFS. The significance of the prognostic impact differed according to the tumor location. Cancer 2017;123:3513-23.
BACKGROUND:Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor β [TGF-β]) was performed for 516 patients with stage III or high-risk stage II CRC treated with surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy. The associations between critical pathway mutations and relapse-free survival (RFS) and overall survival were analyzed. The associations were further analyzed according to the tumor location. RESULTS: The mutation rates for the WNT, P53, RTK-RAS, PI3K, and TGF-β pathways were 84.5%, 69.0%, 60.7%, 30.0%, and 28.9%, respectively. A mutation in the PI3K pathway was associated with longer RFS (adjusted hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.36-0.99), whereas a mutation in the RTK-RAS pathway was associated with shorter RFS (adjusted HR, 1.60; 95% CI, 1.01-2.52). Proximal tumors showed a higher mutation rate than distal tumors, and the mutation profile was different according to the tumor location. The mutation rates of Kirsten ratsarcoma viral oncogene homolog (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA), and B-Raf proto-oncogene serine/threonine kinase (BRAF) were higher in proximal tumors, and the mutation rates of adenomatous polyposis coli (APC), tumor protein 53 (TP53), and neuroblastoma RAS viral oncogene homolog (NRAS) were higher in distal tumors. The better RFS with the PI3K pathway mutation was significant only for proximal tumors, and the worse RFS with the RTK-RAS pathway mutation was significant only for distal tumors. CONCLUSIONS: A PI3K pathway mutation was associated with better RFS for CRC patients treated with adjuvant chemotherapy, and an RTK-RAS pathway mutation was associated with worse RFS. The significance of the prognostic impact differed according to the tumor location. Cancer 2017;123:3513-23.
Authors: Elizabeth A Kobe; Brian A Sullivan; Xuejun Qin; Thomas S Redding; Elizabeth R Hauser; Ashton N Madison; Cameron Miller; Jimmy T Efird; Ziad F Gellad; David Weiss; Kellie J Sims; Christina D Williams; David A Lieberman; Dawn Provenzale Journal: Gastrointest Endosc Date: 2022-05-07 Impact factor: 10.396
Authors: Syed H Zaidi; Tabitha A Harrison; Amanda I Phipps; Robert Steinfelder; Quang M Trinh; Conghui Qu; Barbara L Banbury; Peter Georgeson; Catherine S Grasso; Marios Giannakis; Jeremy B Adams; Elizabeth Alwers; Efrat L Amitay; Richard T Barfield; Sonja I Berndt; Ivan Borozan; Hermann Brenner; Stefanie Brezina; Daniel D Buchanan; Yin Cao; Andrew T Chan; Jenny Chang-Claude; Charles M Connolly; David A Drew; Alton Brad Farris; Jane C Figueiredo; Amy J French; Charles S Fuchs; Levi A Garraway; Steve Gruber; Mark A Guinter; Stanley R Hamilton; Sophia Harlid; Lawrence E Heisler; Akihisa Hidaka; John L Hopper; Wen-Yi Huang; Jeroen R Huyghe; Mark A Jenkins; Paul M Krzyzanowski; Mathieu Lemire; Yi Lin; Xuemei Luo; Elaine R Mardis; John D McPherson; Jessica K Miller; Victor Moreno; Xinmeng Jasmine Mu; Reiko Nishihara; Nickolas Papadopoulos; Danielle Pasternack; Michael J Quist; Adilya Rafikova; Emma E G Reid; Eve Shinbrot; Brian H Shirts; Lincoln D Stein; Cherie D Teney; Lee Timms; Caroline Y Um; Bethany Van Guelpen; Megan Van Tassel; Xiaolong Wang; David A Wheeler; Christina K Yung; Li Hsu; Shuji Ogino; Andrea Gsur; Polly A Newcomb; Steven Gallinger; Michael Hoffmeister; Peter T Campbell; Stephen N Thibodeau; Wei Sun; Thomas J Hudson; Ulrike Peters Journal: Nat Commun Date: 2020-07-20 Impact factor: 14.919
Authors: Sandra Tapial; Daniel Rueda; María Arriba; Juan Luis García; Lorena Brandáriz; Jessica Pérez; Yolanda Rodríguez; Damián García-Olmo; Rogelio González-Sarmiento; Miguel Urioste; José Perea Journal: Br J Cancer Date: 2018-01-02 Impact factor: 7.640